|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Ann Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tu K, Liu Z, Yao B, Han S and Yang W:
MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT
signaling in hepatocellular carcinoma. Int J Oncol. 48:965–974.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ji H, Chen M, Greening DW, He W, Rai A,
Zhang W and Simpson RJ: Deep sequencing of RNA from three different
extracellular vesicle (EV) subtypes released from the human LIM1863
colon cancer cell line uncovers distinct miRNA-enrichment
signatures. PloS One. 9:e1103142014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang LY, Li B, Jiang HH, Zhuang LW and Liu
Y: Inhibition effect of miR-577 on hepatocellular carcinoma cell
growth via targeting β-catenin. Asian Pac J Trop Med. 8:923–929.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Shen C, Li C, Yang G, Liu H, Chen
X, Zhu D, Zou H, Zhen Y, Zhang D and Zhao S: miR-577 inhibits
glioblastoma tumor growth via the Wnt signaling pathway. Mol
Carcinog. 55:575–585. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Z, Zhang W and Deng F: MicroRNA-577
inhibits gastric cancer growth by targeting E2F transcription
factor 3. Oncol Lett. 10:1447–1452. 2015.PubMed/NCBI
|
|
12
|
Jiang H, Ju H, Zhang L, Lu H and Jie K:
microRNA-577 suppresses tumor growth and enhances chemosensitivity
in colorectal cancer. J Biochem Mol Toxicol. 31:2017. View Article : Google Scholar
|
|
13
|
Chen XY, Li GM, Dong Q and Peng H: MiR-577
inhibits pancreatic β-cell function and survival by targeting
fibroblast growth factor 21 (FGF-21) in pediatric diabetes. Genet
Mol Res. 14:15462–15470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamanaka C, Wada H, Eguchi H, Hatano H,
Gotoh K, Noda T, Yamada D, Asaoka T, Kawamoto K, Nagano H, et al:
Clinical significance of CD13 and epithelial mesenchymal transition
(EMT) markers in hepatocellular carcinoma. Jpn J Clin Oncol.
48:52–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vincent CT and Fuxe J: EMT, inflammation
and metastasis. Semin Cancer Biol. 47:168–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Ftx non coding RNA-derived
miR-545 promotes cell proliferation by targeting RIG-I in
hepatocellular carcinoma. Oncotarget. 7:25350–25365.
2016.PubMed/NCBI
|
|
19
|
Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yao Y,
Liu Q and Song T: RIG-I suppresses the migration and invasion of
hepatocellular carcinoma cells by regulating MMP9. Int J Oncol.
46:1710–1720. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression
of microRNA-129-2 suppresses cell aggressiveness by inhibiting high
mobility group box 1 in human hepatocellular carcinoma. Oncotarget.
7:36909–36923. 2016.PubMed/NCBI
|
|
21
|
Liu Z, Dou C, Wang Y, Jia Y, Li Q, Zheng
X, Yao Y, Liu Q and Song T: High-mobility group box 1 has a
prognostic role and contributes to epithelial mesenchymal
transition in human hepatocellular carcinoma. Mol Med Rep.
12:5997–6004. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zha TZ, Hu BS, Yu HF, Tan YF, Zhang Y and
Zhang K: Overexpression of HOXA1 correlates with poor prognosis in
patients with hepatocellular carcinoma. Tumour Biol. 33:2125–2134.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q,
Yang W, Zheng X, Tu K and Liu Q: miR-187-3p inhibits the metastasis
and epithelial-mesenchymal transition of hepatocellular carcinoma
by targeting S100A4. Cancer Lett. 381:380–390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan X, He J, Sun F and Gu J: Effects and
interactions of MiR-577 and TSGA10 in regulating esophageal
squamous cell carcinoma. Int J Clin Exp Pathol. 6:2651–2667.
2013.PubMed/NCBI
|
|
25
|
Li Z, Feng S, Zhou L, Liu S and Cheng J:
NS5ATP6 modulates intracellular triglyceride content through FGF21
and independently of SIRT1 and SREBP1. Biochem Biophys Res Commun.
475:133–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Q, Zhang X, Li N, Liu Q and Chen D:
miR-30b inhibits cancer cell growth, migration, and invasion by
targeting homeobox A1 in esophageal cancer. Biochem Biophys Res
Commun. 485:506–512. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Liu G, Shen D, Ye H, Huang J, Jiao
L and Sun Y: HOXA1 enhances the cell proliferation, invasion and
metastasis of prostate cancer cells. Oncol Rep. 34:1203–1210. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Li Y, Qi W, Zhang N, Sun M, Huo Q,
Cai C, Lv S and Yang Q: MicroRNA-99a inhibits tumor aggressive
phenotypes through regulating HOXA1 in breast cancer cells.
Oncotarget. 6:32737–32747. 2015.PubMed/NCBI
|
|
29
|
Kraft S, Moore JB, Muzikansky A, Scott KL
and Duncan LM: Differential UBE2C and HOXA1 expression in
melanocytic nevi and melanoma. J Cutan Pathol. 44:843–850. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiao F, Bai Y, Chen Z, Li Y, Luo L, Huang
J, Yang J, Liao H and Guo L: Downregulation of HOXA1 gene affects
small cell lung cancer cell survival and chemoresistance under the
regulation of miR-100. Eur J Cancer. 50:1541–1554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan C, Zhu X, Han Y, Song C, Liu C, Lu S,
Zhang M, Yu F, Peng Z and Zhou C: Elevated HOXA1 expression
correlates with accelerated tumor cell proliferation and poor
prognosis in gastric cancer partly via cyclin D1. J Exp Clin Cancer
Res. 35:152016. View Article : Google Scholar : PubMed/NCBI
|
